Moxifloxacin: new preparation. A me-too with more cardiac risks.
(1) Moxifloxacin is the fourth fluoroquinolone to be licensed in France with indications covering ENT and respiratory tract infections. (2) In community-acquired pneumonia, acute bacterial sinusitis and acute exacerbations of chronic bronchitis, moxifloxacin seems no more effective than other fluoroquinolones available in France (with which it has not been compared) or the other antibiotics with which it has been compared. (3) Moxifloxacin has the usual adverse effects of fluoroquinolones, but carries a greater risk of QT prolongation than ciprofloxacin, levofloxacin and ofloxacin.
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000009:adverse effects / Q000627:therapeutic use; D017277:Drug Approval; D024841:Fluoroquinolones / Q000009:adverse effects* / Q000627:therapeutic use; D005602:France; D006801:Humans; D064704:Levofloxacin; D008133:Long QT Syndrome / Q000139:chemically induced; D015242:Ofloxacin / Q000009:adverse effects / Q000627:therapeutic use; D011014:Pneumonia / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D002939:Ciprofloxacin; D064704:Levofloxacin; D015242:Ofloxacin